Back to search results

Interstitial Brachytherapy for Unresectable Kidney Cancer

This study is testing a treatment called interstitial brachytherapy for kidney cancer that cannot be removed by surgery or other procedures. Interstitial brachytherapy is a type of internal radiation therapy where a radiation source is placed directly into or near the tumor to shrink it. Researchers want to see if this treatment is safe and how well it controls the growth of large kidney tumors. You might be able to join if you have kidney cancer (Stage I or II Renal Cell Cancer) with a tumor between 4 and 10 cm, and you are not able or willing to have surgery. The study aims to find out if this treatment can reduce tumor size and lower the risk of cancer spreading. The study is currently unclear on its recruitment status and plans to enroll 17 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 17 participants.
What's involved
You would undergo interstitial brachytherapy for 1-2 sessions. These sessions could be on the same day or over two separate days within two weeks.
Compensation
Not stated in the trial record.
Follow-up
After treatment, you will have follow-up appointments every 3 months for at least 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04473781

Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

Terminated
PHASE1Ages 18+InterventionalTreatment
Jonsson Comprehensive Cancer Center
~2 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Interstitial Radiation Therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose limiting toxicity (DLT)
Measured over From the first administration of study therapy up to 60 days
+1 more outcome measured

Conditions

Stage I Renal Cell Cancer
Stage II Renal Cell Cancer

Explore related trials

Renal Cell Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Albert J Chang · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Elected to undergo interstitial brachytherapy as part of conventional treatment for renal cell carcinoma
Biopsy proven renal cell carcinoma
No definitive evidence of locally advanced (nodal or tumor thrombus) or distant (metastatic) disease
Lesion size (maximal dimension) of 4 to 10 cm
Patient not a candidate for curative surgery (unwilling or unable to pursue surgery)
Lesion cannot be reliably treated with ablative techniques
Entire lesion able to be treated adequately by brachytherapy per radiation oncologist
Tumor predominantly solid (\~ \> 80%)
Lesion that has been observed for \>= 6 months with demonstrable growth rate anticipated to be \>= 4 mm/year by same imaging modality
Renal tumor that is amenable to percutaneous access for interstitial renal brachytherapy (Institutional Review Board \[IRB\])
Hemoglobin \> 9
Absolute neutrophil count (ANC) \>= 1500/uL (microliter)
Platelets \>= 100,000/uL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3.0 upper limit of normal (ULN)
Total bilirubin =\< ULN
A competent immune system
Estimated glomerular filtration rate (eGFR) \>= 30
Good performance status (Eastern Cooperative Oncology Group \[ECOG\]) \< 2
Understanding and willingness to provide consent
No prior systemic treatment for kidney cancer
Women of childbearing potential must have negative pregnancy test at start of therapy

Exclusion

Presence of an active, untreated, non-renal malignancy
Uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction within 6 months
History of bleeding diathesis or recent bleeding episode
Need for urgent treatment of renal cancer due bleeding, pain, or paraneoplastic syndrome
Prior surgery or radiation therapy to the operative site
Unwillingness to undergo clinical and laboratory monitoring and/or imaging studies

What this trial measures

  • Dose limiting toxicity (DLT)From the first administration of study therapy up to 60 days

    A 3+3 safety lead-in phase will be employed in order to determine the DLT for interstitial renal brachytherapy. Grading of DLTs will follow the guidelines provided in the Common Terminology Criteria for Adverse Events version 5.0 criteria.

  • One year (12-month) linear growth rateAt 1 year

    Adequate local control will be defined as minimal growth kinetics (=\< 1 mm/year) on 1 year follow-up.